Small molecules & peptides
(2S,4R)-4-Fluoroglutamine precursor
Precursor for (2S,4R)-4-[¹⁸F]Fluoroglutamine
L-Glutamine, N²-[(1,1-dimethylethoxy)carbonyl]-4-[[(4-methylphenyl)sulfonyl]oxy]-N-[(2,4,6-trimethoxyphenyl)methyl]-, 1,1-dimethylethyl ester, (4S)-; tert-butyl (2S,4S)-2-((tert-butoxycarbonyl)amino)-5-oxo-4-(tosyloxy)-5-((2,4,6-trimethoxybenzyl)amino)pentanoate; (2S,4R)-4-[¹⁸F]Fluoroglutamine precursor
(2S,4S)-tert-butyl-2-(tert-butoxycarbonylamino)-5-oxo-4-(tosyloxy)-5-(2,4,6-trimethoxybenzylamino)pentanoate
Quality
Research Chemical
Characteristics
Molar mass 652.75
CAS RN [1262523-66-9]
Purity ≥ 95 %
- Colorless to off-white solid
- soluble in dimethyl sulfoxide, dichloromethane, chloroform, ethyl acetate
Certificates
CoA: appearance, ¹H NMR spectrum (identity), HPLC (purity)
Literature
Qu W. et al. Synthesis of Optically Pure 4-Fluoro-Glutamines as Potential Metabolic Imaging Agents for Tumors. J. Am. Chem. Soc. 2011, 133, 1122–1133.
Lieberman B. P. et al. PET Imaging of Glutaminolysis in Tumors by ¹⁸F-(2S,4R)4-Fluoroglutamine. J. Nucl. Med. 2011, 52, 1947–1955.
Xu X. et al. Imaging Brain Metastasis Patients With ¹⁸F-(2S,4R)-4-Fluoroglutamine. Clin. Nucl. Med. 2018, 43, e392–e399.
Grkovski M. et al. Pharmacokinetic assessment of ¹⁸F-(2S,4R)-4-fluoroglutamine in patients with cancer. J. Nucl. Med. 2020, 61, 357–366.
Xu X. et al. Dynamic PET/CT imaging of ¹⁸F-(2S,4R)4-fluoroglutamine in healthy volunteers and oncological patients. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 2280–2292.
Add to inquiry
| Product | Product No. | Filling amount | Quantity | ||
|---|---|---|---|---|---|
| /products/small-molecules-and-peptides/chemical/5d074e30-6282-48ff-bb2d-3e4abb601939 | Precursor | Product No.: 3198 |
Product was added